The Henry Ford Health System in Detroit has been selected as a trial site for a potential COVID-19 vaccine.
Johnson & Johnson’s Phase 3 Clinical Research Study, the Ensemble Trial ‘Johnson Pharmaceuticals’ Johnson & zwnj; As Ad26.COV2.S, according to a news release.
“We are honored to be one of three sites in Michigan to participate in the 3rd phase trials for Johnson’s COVID-19 vaccine candidate,” said Adnan Munkara, Henry Ford Health System Executive Vice President and Chief Clinical Officer. “The Henry Ford Health System led the way in the treatment of COVID-19, as well as the study and development of potential vaccines and innovative therapies. We believe that participation in this latest trial is an important part of our effort to stop this latest epidemic.”
The health system said the recruitment of volunteers to take part in the vaccination trial would begin soon. Anyone interested in volunteering can find details about the trial and sign up here.
Phase 3 is a randomized, double-blind, placebo-controlled clinical trial aimed at assessing the safety and efficacy of a single vaccine dose of placebo, versus jancine COVID-19 vaccine candidate, among approximately 60,000 adults over 60 years of age in the United States and internationally, including significant ones. Representation among study participants.
This trial includes people with and without comorbidity who are at high risk for progression to severe COVID-19. Henry Ford Health System researchers record adults aged 18 or older from southeastern Michigan.
“We hope that residents of southeastern Michigan will consider participating in the vaccine trial, especially those who are at risk of contact with the virus and those who are likely to develop serious symptoms,” Munkara said. “I would like to thank everyone who volunteered to support the global effort to combat COVID-19.”
As of Thursday morning, more than 192,000 cases of coronavirus had been confirmed in Michigan. The virus has killed 7,419 people in the state, state health officials said.